Letters to the Editor
Early Access
When anti-tumor necrosis factor-α backfires: paradoxical psoriasis and psoriatic arthritis in a patient with hidradenitis suppurativa
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 11 September 2026
147
Views
7
Downloads
Authors
Dear Editor,
Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the folliculoapocrine units. Biological therapies, historically led by the anti-tumor necrosis factor (TNF)-α antibody adalimumab, have transformed severe HS management. Recently, interleukin (IL)-17 inhibitors (secukinumab, bimekizumab) were also approved in Europe for moderate-to-severe HS. However, TNF-α blockade can paradoxically induce or exacerbate inflammatory skin and joint conditions, including psoriasis (incidence 1-5%) and psoriatic arthritis. We report a case of paradoxical inverse psoriasis and suspected early psoriatic arthritis induced by adalimumab in an HS patient, successfully managed by switching to secukinumab. [...]
Downloads
Download data is not yet available.
Citations
1. Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012;366:158-64.
2. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539-61.
3. Kimball AB, Okun MM, Williams DA, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med 2016;375:422-34.
4. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy. Ann Rheum Dis 2010;69:97-102.
5. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012;9:496-503.
6. Tsiogka A, Liakou AI, Agiasofitou E, et al. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa. Dermatology 2023;239:937-41.
7. Lian N, Zhang L, Chen M. Tumor necrosis factors-α inhibition-induced paradoxical psoriasis: A case series and literature review. Dermatol Ther 2020;33:e14225.
8. Ruggiero A, Martora F, Picone V, et al. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. Biomedicines 2022;10:455.
9. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014;63:567-77.
10. Vignoli CA, Gargiulo L, Sanna F, et al. Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa. J Dermatolog Treat 2023;34:2256905.
11. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-9.
12. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 2023;401:747-61.
13. Marasca C, Megna M, Balato A, et al. Secukinumab and hidradenitis suppurativa: Friends or foes? JAAD Case Rep 2019;5:184-7.
How to Cite
1.
Del Re C, Filastro V, Fasano G, Valenti G, D'Amico D. When anti-tumor necrosis factor-α backfires: paradoxical psoriasis and psoriatic arthritis in a patient with hidradenitis suppurativa. Dermatol Reports [Internet]. 2026 Sep. 11 [cited 2026 Sep. 14];. Available from: https://journals.pagepress.net/dr/article/view/10808
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
